This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

IPO Watch: 2011

Kips Bay Medical

IPO Filing Date: Apr. 8. 2010

Expected IPO Date: Feb. 10, 2011

Amount of Proceeds Sought: ~$25 million

Expected Offering Price: $8 to $10

Expected Number of Shares to Be Sold: ~ 2.75 million

Use of Proceeds: To seek regulatory approval to market its eSVS Mesh product in the U.S. and overseas. The company said the product can improve bypass procedures for heart patients.

Expected Ticker Symbol: KIPS (KIPS) (NASDAQ)

Lead Underwriters: Rodman & Renshaw (RODM) and Newbridge Securities

Co-Managers: Caris & Company

About the Company: Kips Bay Medical is a medical device company currently in development stage.

The company is focusing on developing, manufacturing and commercializing its eSVS MESH product for coronary artery bypass surgeries. The company said the product can improve the long-term results of these surgeries.

The company began shipping its eSVS MESH in European Union markets in Jun. 2010 and the United Arab Emirates in Oct. 2010, but hasn't generated significant revenues yet. The U.S. Food and Drug Administration is currently reviewing Kips' application for the product. If granted, Kips Bay would be able to begin U.S. clinical trials for the project.

The company expects enrollment in the clinical trials to begin in the first half of 2011.

Kips Bay experienced net losses of $3.3 million and $10.1 million in the year ended Dec. 31, 2009 and the nine months ended Oct. 2, 2010, respectively. The company's net loss for the nine months ended Oct. 2 included a non-cash charge of $2.3 million due to a modification in an investor stock purchase option and a $5 million charge in connection with its first milestone payment to Medtronic (MDT), one year after the first sale of its eSVS MESH. The two have an intellectual property agreement over the product.

One of the biggest risks about Kips Bay is its limited history. The company expects more losses in the future.

Competitors: Kips Bay said there are at least two companies that develop mesh devices for coronary procedures, but none of their products directly compete with Kips'. These companies include Swiss company Alpha Research and Germany company B. Braun.

IPO Scorecard:

Actual IPO Date: Feb. 10

Actual Proceeds Raised: $17 million

Actual Offering price: $8

Actual Number of Shares Sold: 2.1 million

First Day Closing Price: $7.93

IPO First Day Return: -0.9

>>Search for Highest Dividends by Rate or Yield

More on Earnings
Today's Top Earnings
Earnings Calendar

-- Written by Andrea Tse in New York.

>To contact the writer of this article, click here: Andrea Tse.

>To follow the writer on Twitter, go to Andrea Tse.

>To submit a news tip, send an email to:

Copyright 2010 Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
9 of 9

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs